ArticleScientific reports2025
Exploring the role of chitosan and curcumin-loaded chitosan nanoparticles against chronic toxoplasma infection in experimental mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sustained ocular drug delivery via polydopamine chitosan curcumin nanocomposite coatings.Discover nano · 2026Article
- Biosynthesized chitosan nanoparticles from Krameria lappacea: a strategy to ameliorate coccidiosis-induced intestinal dysfunction.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Toxoplasma gondii infection remains a significant global health concern, promoting the urgent need for effective therapeutic strategies. This study aimed to evaluate the therapeutic potential of chitosan nanoparticles (CSNPs) and curcumin-loaded chitosan nanoparticles (Cur-CSNPs) against the chronic Toxoplasma gondii (ME49 strain) in an experimental mouse model. This achieved by investigating their ability to reduce parasitic load, oxidative stress, histopathological lesion, and to enhance the host immune response. Sixty female BALB/c mice were divided into five groups: infected untreated group, Spiramycin®-treated group, CSNPs-treated group, Cur-CSNPs-treated group, and negative control group. The Cur-CSNPs-treated group exhibited the lowest brain cyst counts, along with significant reductions in cyst size. Hematological indices revealed no significant reduction in total white blood cell (WBC) counts or in the percentage of neutrophils, monocytes, and eosinophils in both the CSNPs and Cur-CSNPs treated groups, compared to the infected untreated group and Spiramycin-treated group. However, both nanoparticle-treated groups exhibited a significant decrease in the percentage of lymphocytes compared to the infected untreated group. Significant differences in total antioxidant capacity (TAC) and malondialdehyde (MDA) levels were observed, with the Cur-CSNPs treated group displaying values comparable to the negative control. Histopathological examination revealed substantial improvements in the brain, liver, and spleen tissues of Cur-CSNPs-treated animals, characterized by preserved tissue architecture and reduced inflammatory lesions. Immunohistochemical analysis further revealed reduced expression of IL-6 and TNF-α, indicating a mitigated inflammatory response. These findings highlight the promising therapeutic role of Cur-CSNPs in controlling chronic T. gondii infection and suggest their potential as a novel strategy for developing effective antiparasitic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.